Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Grade Non-Muscle Invasive Bladder Cancer

NCT04179162 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04179162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Grade Non-Muscle Invasive Bladder Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 22, 2019
Completion date
November 30, 2027
Enrollment
54 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer (nmibc)